Klimanskaya Irina, Rosenthal Nadia, Lanza Robert
Advanced Cell Technology, 381 Plantation Street, Worcester, Massachusetts 01605, USA.
Nat Rev Drug Discov. 2008 Feb;7(2):131-42. doi: 10.1038/nrd2403.
Although great progress has been made in the isolation and culture of stem cells, the future of stem-cell-based therapies and their productive use in drug discovery and regenerative medicine depends on two key factors: finding reliable sources of multipotent and pluripotent cells and the ability to control their differentiation to generate desired derivatives. It is essential for clinical applications to establish reliable sources of pathogen-free human embryonic stem cells (ESCs) and develop suitable differentiation techniques. Here, we address some of the problems associated with the sourcing of human ESCs and discuss the current status of stem-cell differentiation technology.
尽管干细胞的分离和培养已取得了巨大进展,但基于干细胞的疗法的未来以及它们在药物发现和再生医学中的有效应用取决于两个关键因素:找到多能和全能细胞的可靠来源以及控制它们分化以产生所需衍生物的能力。建立无病原体的人类胚胎干细胞(ESC)的可靠来源并开发合适的分化技术对于临床应用至关重要。在此,我们讨论与人类ESC来源相关的一些问题,并探讨干细胞分化技术的现状。